A Phase II Trial of Post-Transplant Cyclophosphamide and Sirolimus for Graft-versus-host Disease (GVHD) Prophylaxis Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Incidence of GVHD
To estimate the incidence of graft-versus-host disease (GVHD) when utilizing post-transplant cyclophosphamide (Cy) and sirolimus for GVHD prophylaxis following reduced intensity allogeneic hematopoietic stem cell transplantation (SCT) in patients with high risk hematologic malignancies.
Scott R Solomon, MD
Blood and Marrow Transplant Group of Georgia
United States: Food and Drug Administration
|Northside Hospital||Atlanta, Georgia 30342|